LENZ SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 11, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 24, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 30, 2025

News

TYPE

HEADLINE

FILED AT

8-K

LENZ Therapeutics Reports Q3 2026 Financial Results, Announces Strategic Reorganization and CEO Succession

Oct 28, 2026

8-K

LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Aug 11, 2026

8-K

LENZ Therapeutics Announces Resignation of Director Zach Scheiner and Board Reorganization

Jul 2, 2026

8-K

LENZ Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 12, 2026

8-K

LENZ Therapeutics Reports Q1 2026 Financial Results and Commercial Progress for VIZZ®

May 11, 2026

8-K

LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Mar 24, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

April ATM | Offering amount: $150,000,000

Apr 14, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 13,070,093 | Warrants amount: 147,642

Apr 14, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 1,578,947

Apr 9, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 1,022,809

Apr 9, 2025

424B3

UPDATED

Nov 6, 2024

424B3

UPDATED

Nov 6, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 24, 2026

S-3

April 2025 SHELF

Apr 4, 2025

S-3

SHARE RESALE REGISTRATION | Shares amount: 13,070,093 | Warrants amount: 147,642

Apr 4, 2025

POS AM

Form POS AM - Post-Effective amendments for registration statement

Apr 4, 2025

POS AM

Form POS AM - Post-Effective amendments for registration statement

Apr 4, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 19, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Jun 6, 2023

DEF 14A

Form DEF 14A - Other definitive proxy statements

Jun 6, 2023

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

FMR LLC (Filed by)

Nov 5, 2026

SCHEDULE 13G

BML Investment Partners, L.P. (Filed by)

Nov 4, 2026

Chevallard Daniel R. (Reporting)

Nov 3, 2026

SCHEDULE 13D/A

RA CAPITAL MANAGEMENT, L.P. (Filed by)

Nov 2, 2026

RA Capital Healthcare Fund LP (Reporting)

Nov 2, 2026

SCHEDULE 13G

BlackRock Portfolio Management LLC (Filed by)

Oct 27, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 15, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 15, 2025

CORRESP

Form CORRESP - Correspondence

Apr 10, 2025

CORRESP

Form CORRESP - Correspondence

Apr 10, 2025

LETTER

Form UPLOAD - SEC-generated letter

Apr 10, 2025

LETTER

Form UPLOAD - SEC-generated letter

Apr 10, 2025

LENZ Therapeutics, Inc. LENZ · SEC Filings